Last-Resort drug teclistamab made available for desperate myeloma patients
NCT ID NCT05161598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides pre-approval access to teclistamab for people with relapsed or refractory multiple myeloma who have no other treatment options left. Participants must have tried and failed all standard therapies, including proteasome inhibitors, IMiDs, and anti-CD38 antibodies. The goal is to offer a potential treatment option when no others are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.